Close Menu
December 17, 2019
Sponsored by
Thermo Fisher Scientific

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

GenomeWebinar

Co-Director, Solid Tumor and Constitutional Disease Diagnostic Laboratory,
University of Navarra

This webinar reviews how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Liquid biopsy enables the study of tumor-specific circulating components, including circulating tumor cells (CTCs), circulating cell-free tumor DNA (ctDNA) and RNA (ctRNA). The approach brings both great potential and new challenges to precision medicine.

This webinar highlights two key aspects of successful implementation of liquid biopsy in the laboratory: proficiency testing and interlaboratory comparison. Additionally, our speaker, Dr. Gorka Alkorta-Aranburu of University of Navarra, discusses specifics of the liquid biopsy methodology, including properties of cell-free nucleic acids and considerations for next-generation sequencing technology.

Learning objectives:

  • The benefits of liquid biopsy as a non-invasive method to better understand cancer development and treatment.
  • The advantages (and challenges) of an NGS approach to study circulating cell-free nucleic acids for clinical applications.
Sponsored by

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
24
Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.